Cordis Corporation

Ethicon, Gmbh

Wyeth

Other

Alcon Laboratories, Inc.

Ethicon, Inc. - USA

Cordis Corportation

Cilag International Gmbh

Omrix Biopharmaceuticals Inc.

Cardinal Health Switzerland 515 Gmbh

David C. Lentz

Gerard H. Llanos

Robert Falotico

Gregory a. Kopia

John Siekierka

Gerard H Llanos

Ronald Rakos

Carol Lynn Wright

Mark B Roller

Kristen King

Angelo G Scopelianos

Pallassana V Narayanan

Sai Veruva

Jianguo Jack Zhou

Gregory A Kopia

David Christian Lentz

Joseph Vliet

Andrew James Carter

Cynthia Anne Maryanoff

Dwayne Lee Looney

Clifford A Dey

Robert W Van Holten

Kenneth Michael Keilman

John J Siekierka

Markus Bohn

George Papandreou

Syed F Hossainy

Allan Sachs Hoffman

Kevin Shaun Weadock

Yi-Lan Wang

James H Silver

Ashley DeAnglis

Nir I Nativ

Luis A Davila

Johannes Caspar Mathias Elizabeth Bender

Anilbhai S Patel

David J Wilson

George Landau

Jacob Leidner

Alan Roy Pelton

John J Spaltro

David Cook

Karel Six

William D Shaw, Jr

Jorge Orlando Mendez

Karl K Scheidt

Christine Trepanier

Joost Opsteen

Abraham Reinier Keereweer

Aaron D Pesnell

Hans-Steffen Schacht

Avner Brandes

Thomas Weindl

William L Rion

Thomas L Todd

Karin Maria Balss

Carol Wright

David C Lentz

Vladimir Veselov

Kristin King

Eugena A Akerman

Xuejun Jay Liu

Dirk Cleeren

Wilai Kosol

Georgios Papandreou

William Douglas Shaw, Jr

William Rion

Ashley P Deanglis

Rosa Pilar FÉLIX Lanao

Kirsten King

Jorge O Mendez

Alan R Pelton

Andrew J Carter

The present invention is directed to an absorbable hemostatic nonwoven patch that utilizes a biocompatible substrate comprised of melt-blown microfibers as webbed sheets that are layered and bonded/entangled in descending density and ascending porosity; with the substrate having a high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ability for laparoscopic use or trocar deployment, ultimately for functional use as a highly effective hemostat in addressing problematic bleeding during both open and minimally invasive surgical procedures.

Melt blown dressing with gradient density

The present invention is directed to multi-layered wound dressings having a carrier layer, at least two sublayers, wherein each sublayer contains at least one reactive, cross-linkable component and the at least two reactive, cross-linkable components are co-reactive with the other and at least one reactive, cross-linkable has a protective leaving group and a buffering salt agent.

Sealant dressing with protected reactive components

The present invention is directed to medical devices having a first porous substrate layer with at least a surface coating thereon of a first co-reactive component and a second substrate layer with at least a surface coating layer of a second co-reactive component that reacts with the first co-reactive component, and a removable barrier layer positioned between the first substrate layer and second substrate layer and in contact with said first substrate layer and said second substrate layer.

Sealant dressing with removable intermediate separating layer

The present invention is directed to an absorbable hemostatic patch that utilizes a biocompatible fibrous, fabric substrate that is melt-blown and napped or loosened at the surface, with the substrate having a low-profile, high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ultimately effective for use as a hemostat in situations of problematic bleeding.

Napped coated wound dressing

An absorbable hemostatic nonwoven patch utilizes a biocompatible substrate comprised of melt-blown microfibers as webbed sheets that are layered and bonded/entangled in descending density and ascending porosity; the substrate having a high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ability for laparoscopic use or trocar deployment, ultimately for functional use as a highly effective hemostat in addressing problematic bleeding during both open and minimally invasive surgical procedures.

A hemostatic pad comprising a bioabsorbable scaffolding material; a lyophilized thrombin powder, a lyophilized fibrinogen powder, and a meltable binder powder, with all powders disposed on the bioabsorbable scaffolding material. A meltable binder such as PEG bonds the lyophilized thrombin powder and the lyophilized fibrinogen powder to the bioabsorbable scaffolding material for improved friability, wettability and performance in a use, such as for hemostatic treatment or sealing at a wound site.

Hemostatic bioabsorbable device with polyethylene glycol binder

An engagement head for engaging a porous substrate includes at least two pin sets, each pin set including a plurality of pins arranged in a plurality of parallel pin rows at a predetermined pin angle, wherein pins of immediately neighboring pin rows are arranged such that pin angles for the pins in a pin row are inversely symmetrical to pin angles for the pins in a neighboring pin row. The pins of a pin row move collectively in the same direction when a pin set is extended, which direction is determined by the pin angle of the pin row, whereby neighboring pin rows move in opposite longitudinal directions from one another when the pin set is extended. The pin sets may be extended and retracted in unison by a single actuation source.

Process and apparatus for coating a porous substrate with a coating liquid

The present disclosure pertains to stents having a coating applied thereto, wherein the coating comprises a biocompatible polymer/drug mixture, as well as devices comprising a metallic stent, a biocompatible polymeric carrier and a drug.

Methods and devices for delivering therapeutic agents to target vessels

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

Coated medical devices

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

Drug/drug delivery systems for the prevention and treatment of vascular disease

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Heparin barrier coating for controlled drug release

Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-based polymeric coating facilitates the performance of such devices in inhibiting restenosis.

Processes for coating implantable medical devices that improve the stability of therapeutic agents contained within the coating.

Method of coating stents

Growing community of inventors

Stewartsville, NJ, United States of America

Gerard H Llanos